WUXI BIOLOGICS UNSP.ADR/2 Logo
US98260N1081

WUXI BIOLOGICS UNSP.ADR/2

Ins Portfolio

Kurse werden geladen...

Prognose

Kaufen
  1
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

    WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

    Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million Added 151 new integrated projects, including 13 in late-stage and commercial stage Total integrated projects reached 817, one of the largest portfolios of complex biologics Research Services enabled 7 global programs for molecule discovery, eligible to receive ~$140 million in near-term payments Completed 16 PPQs in 2024, with 24 PPQs scheduled for 2025 Strengthened global presence to support continued business momentum HONG KONG , March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2024 ("Reporting Period"). Financial Highlights Revenue: For the year ended December 31, 2024, the Group's revenue grew 9.6% YoY to RMB18,675.4 million, with non-COVID revenue increasing 13.1% YoY.» Mehr auf prnewswire.com

  • Foto von WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

    WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

    SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.» Mehr auf prnewswire.com

  • Foto von WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

    WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

    Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI , March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual "A List" for the second year. According to CDP's scoring methodology, companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte WUXI BIOLOGICS UNSP.ADR/2 einen Umsatz von +1,10 Mrd und ein Nettoeinkommen von +192,17 Mio
(EUR)Juni 2024
YOY
Umsatz+1,10 Mrd-
Bruttoeinkommen+429,43 Mio-
Nettoeinkommen+192,17 Mio-
EBITDA+317,01 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+13,44 Mrd
Anzahl Aktien
2,12 Mrd
52 Wochen-Hoch/Tief
+6,69 - +2,36
DividendenNein
Beta
0,73
KGV (PE Ratio)
+41,28
KGWV (PEG Ratio)
1,89
KBV (PB Ratio)
+2,67
KUV (PS Ratio)
+6,06

Unternehmensprofil

WuXi Biologics (Cayman) Inc. bietet End-to-End-Lösungen und -Dienstleistungen für die Erforschung, Entwicklung und Herstellung von Biologika in der Volksrepublik China, Nordamerika, Europa und international an. Darüber hinaus bietet das Unternehmen Beratungsdienstleistungen in Bezug auf biopharmazeutische Technologien, internationale Vertriebsverträge, Tests und Entwicklung von Testtechnologien, Vertriebs- und Marketingdienstleistungen sowie klinische und Produktionsdienstleistungen für Biologika, Produktion und Verkauf von Arzneimitteln, CDMO für Impfstoffe und damit verbundene Tätigkeiten sowie Materiallieferungen. WuXi Biologics (Cayman) Inc. hat strategische Partnerschaften mit ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4 und Exelixis Inc. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in Wuxi, China.

Name
WUXI BIOLOGICS UNSP.ADR/2
CEO
Dr. Zhisheng Chen Ph.D.
SitzWuxi,
USA
Website
Börsengang
Mitarbeiter12.575

Ticker Symbole

BörseSymbol
Pnk
WXXWY
Frankfurt
1FW1.F
München
1FW1.MU

Assets entdecken

Shareholder von WUXI BIOLOGICS UNSP.ADR/2 investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr